儿科初级保健实施SMART哮喘疗法的障碍
OBJECTIVES: To characterize awareness, use, and perceived barriers to implementing single maintenance and reliever therapy (SMART) in primary care for children aged 5 years or older, hypothesizing high clinician awareness but limited use due to multilevel clinician-, system-, and…
要点
- 儿科初级保健医生普遍知晓SMART但使用有限,尤其在年幼患儿中。
- 系统层面保险覆盖和事先授权要求限制SMART采纳。
- 照护者抵触阻碍短效β受体激动剂的去实施,缺乏SMART专用行动计划是跨场景障碍。
核心结论
- 儿科初级保健医生认可SMART疗法,但实施和短效β受体激动剂去实施面临持续的多层障碍。
主要发现
- SMART认知普遍,但在符合条件的儿科患者中使用有限,尤其在年幼儿童中。
- 医生认为SMART有效且符合指南,但描述多层级实施障碍。
- 定性分析识别三个主题:SMART临床有益但操作困难;系统和工作流程障碍限制采纳;照护者抵触阻碍短效β受体激动剂去实施。
- 缺乏SMART专用哮喘行动计划是跨护理场景的关键障碍。
临床怎么用
- 可考虑采用实践促进、审计反馈和电子健康记录生成SMART专用哮喘行动计划等实施策略,以支持更一致地采纳儿科指南一致性哮喘护理。
局限性
- 调查应答率为27.5%,样本量有限,可能影响结果代表性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To characterize awareness, use, and perceived barriers to implementing single maintenance and reliever therapy (SMART) in primary care for children aged 5 years or older, hypothesizing high clinician awareness but limited use due to multilevel clinician-, system-, and caregiver barriers. METHODS: We conducted a sequential explanatory mixed-methods study among pediatric primary care clinicians within a practice-based research network. Clinicians completed a survey assessing SMART awareness, prescribing practices, and perceived barriers, guided by the Consolidated Framework for Implementation Research (CFIR) 2.0. Semistructured interviews were conducted with purposively sampled clinicians to explore factors influencing SMART implementation. Qualitative data were analyzed using an inductive-deductive approach and mapped to CFIR 2.0 constructs. RESULTS: Fifty-two clinicians (27.5%) completed the survey, and 24 completed interviews. Awareness of SMART was universal, but use remained limited among eligible pediatric patients, particularly younger children. Clinicians viewed SMART as effective and guideline-concordant but described multilevel barriers to routine implementation. Qualitative analysis identified 3 themes: (1) SMART is clinically advantageous but challenging to operationalize; (2) system-level and workflow barriers, including insurance coverage and prior authorization requirements, constrain adoption; and (3) caregiver resistance impedes deimplementation of short-acting β-agonists. Absence of SMART-specific asthma action plans emerged as a key barrier across care settings. CONCLUSION: Pediatric primary care clinicians endorse SMART therapy but face persistent clinician-, system-, and caregiver-level barriers to its implementation and to the deimplementation of short-acting β-agonists. Implementation strategies incorporating practice facilitation, audit and feedback, and electronic health record-generated SMART-specific asthma action plans may support more consistent uptake of pediatric guideline-concordant asthma care.
引用
- Peled J, Dodd S, Graham S, et al. Barriers to Implementing SMART for Asthma in Pediatric Primary Care. Pediatrics. 2026. PMID: 42386202. doi:10.1542/peds.2026-076324
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。